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Abstract 
Introduction: The results of clinical investigation of several pyoinflammatory diseases 
are presented. 
Objectives: On clinical data of various models of pyoinflammatory diseases – deep 
pyodermia (UCP), chronic salpingooforitis (OHSO), chronic pyelonephritis (CPN), 
authors found a significant mechanism of influence the pathogenesis on the 
manifestation of immunopathology, efficacy and mechanisms of pharmacological 
immunocorrection action. 
Methods: The study included 300 patients with purulent-inflammatory diseases of 
various genesis – UCP, CPN, OHSO. All the patients before and after traditional 
treatment with mono-and combination of immunomodulators of different origin – 
Roncoleukin, Licopide, Superlimph, Derinate, Polyoxidonium, Timogen, Galavit were 
subjected to a standard hemato-immunological examination and additionally model for 
each nosologic forms of diseases, bacteriological and clinical research. Mathematical 
analysis of obtained data was determined the significant differences of parameters from 
a predetermined level, and optionally, key, signal tests, formalized in the form of 
formulas.  
Results and Discussion: A significant impact of three types of the pathogenesis of 
inflammatory diseases on the nature and severity of the hemato-immunological 
disorders in patients are established; the effectiveness and mechanisms of action of the 
modulator Galavit; a lock of a normalizing effect of the traditional treatment of patients; 
increase activity due to additional assignments of 7 options of monocorrectors and three 
of their combinations; the ability of modulating drugs affect not only immunological, 
but also on haematological, bacteriological and clinical characteristics of patients. In 
results, authors are documented a hole effects the action of immune correcting drugs. A 
formalized assessment of the variations in clinical and laboratory parameters of patients 
allowed us to determine diagnostically significant target of each immune factor 
integrally to compare the effect of individual therapy, to establish mechanisms for the 
modification of the function of the lymphoid system in mono- and combination immune 
therapy, due to the inversion of mathematical analysis to identify laboratory evidence 
for selection of specific variants of complex treatment of patients.  
Conclusion: The result of clinical investigation and mathematical analysis of the results 
achieved was the formulation of a 6-level algorithm to identify and addressing treatment 
 
Rus. 
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immunocompromising persons in the form of 7 approved programs for computer-based 
introduction to computer outcome of laboratory examination of patients.  
Keywords: pyoinflammatory diseases, immunotherapy, immunological disorders, 
formalized assessment. 
 
Introduction 
Under natural conditions, when infection 
develops, it forms a complicated pathogenic 
complex that includes accumulation of a lien 
antigens, aggressive factors (endotoxins, acute-
phase proteins, low-molecular nucleic acids 
etc.), and ultra boundary suppression and 
stimulation of immune reactivity, and also 
competition between extra- and intra-cellular 
parasites for defense reaction regulators, 
cytokines, distortion of metabolic processes 
(peroxidation of lipids and proteins), dystrophic 
and other processes. The main method of 
infectious diseases treatment by antibacterial, 
antiviral and other drugs that lyse or limit the 
reproduction of causative agents, haven‘t 
turned to account because these factors have a 
series of substantial weaknesses. Firstly, they 
have no physical ability completely eliminate 
pathogens; secondly, they stimulate the 
adaptation of the pathogens, for instance, to 
antibacterial drugs, and realize corruption 
distortion of defense reactions towards 
deficiency, allergization and autoaggression. At 
the same time, in case of repeated infection of 
larger causative agents (bacteria) by smaller 
ones (viruses), when the causative agents are 
destroyed, the etiology of infection changes, 
etc. All this requires additional comprehensive 
therapeutic influence on the mentioned and 
other mechanisms [1, 2, 3, 4, 5, 6, 7]. 
Immunotherapy of infections. It implies 
that in treatment of chronic and poorly 
responding to conventional therapy diseases, 
they use vaccines, anatoxins, immunoglobulins, 
i.e. etiotropic drugs and pathogenetic treatment 
with use of blood, blood substitutes, plasma, 
nonspecific immunity stimulators etc. A series 
of drugs simultaneously have antimicrobial and 
immune stimulating actions (immunoglobulins, 
plant extracts etc.). Presently, because of 
changes in the natures of infectious diseases 
course, extensive clinical use of drugs that 
suppress immune reactions (corticosteroids, 
wide spectrum antibiotics) and increased 
allergization, it is necessary to free the 
organism from infectious agents extremely 
quickly and restore its destroyed homeostasis 
[8, 9, 10, 11] 
By origin, immunotherapeutic drugs 
subdivide into 4 groups: 1). obtained from 
blood of various organs of humans and animals 
(plasma, immunoglobulins, thymus drugs, 
myelopeptides, interferons, splenin, placenta 
extract, antilymphocytic serum etc.), 
2).obtained from plants (tinctures of 
eleuterococcus, schizandra etc.), 3).stimulators 
of microbial origin (pyrogenal, prodigiosan, 
zymosan, sodium nucleinate, bificol, 
bacteriophages etc.), 4).synthetic drugs 
(levamisole, pentoxyl, methyluracil, hemodez, 
polyoxidonium, licopid, diuciphonum etc.). 
Вy the nature of immunotherapeutic 
action, immunotherapeutic drugs subdivide 
into drugs with specific (directed) action – 
vaccines, anatoxins, immune serums, 
immunoglobulins, and nonspecific organism 
resistance stimulators– blood and its 
preparations, plasma, bificol etc.) [12, 13]. 
Indications for prescription of immune 
stimulators are flaccid course of infectious 
process, its chronization and recurring, sharp 
long-term suppression of the indices of 
nonspecific antiinfection resistance and specific 
immunity in patients. It may also include 
changes in the nature and increased intensity of 
pathological changes, threat of secondary 
infection development and curative use of 
drugs with immunosuppressing properties [12, 
14, 15]. Immunotherapy prescribed in a 
complex with other medical drugs (antibiotics, 
sulfanilamides, corticosteroids). Its efficiency 
depends on the correct assessment of the initial 
condition of the patient's immune reactivity, the 
nature and intensity of pathological changes, 
the choice of optimal drug and dosing schedule. 
It is also necessary to have an idea about the 
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action mechanisms of prescribed drugs, their 
side effects, compatibility with other infection 
treatment methods, allergic properties etc. 
Sometimes, vaccine therapy prescribed in case 
of immune tolerance to a certain AB, may 
render no positive clinical effect and even 
aggravate the condition of immune depression; 
simultaneously, there risk of anaphylactic 
shock is possible, as well as induction of 
autoimmune diseases and toxic shock. Blood 
and plasma transfusion is a good means 
instrument for stimulation of the patient's 
reactivity. However, this method of treatment is 
restrained by stable indications and must be 
performed on the basis of controlling its effect 
on the course of the disease, immunity indices 
and the possibility of allergy. Drugs of 
etiotropic (immune serums, immunoglobulines, 
bacteriophages, interferon) and desintoxication 
action (drugs of blood, plasma, blood 
substitutes) should be prescribed as early as 
possible after the onset of the disease. A series 
of nonspecific stimulators are used at the height 
of disease and in the convalescence period 
(pentoxyl, vitamins, methyluracil) or for 
treatment of complications (ferrocalum, phytin, 
levamisole). Curative vaccines are added to 
patients with lingering and chronic forms of 
disease. The use of polysaccharide preparations 
is contraindicated for fever conditions. 
Eubiotics are not prescribed simultaneously 
with antibiotics and other similar drugs [14, 15, 
16, 17].  
Nonspecific immunomodulation 
(immunotherapeutic support) of infections 
It implies not only correction of immune, 
but also normalization of hematological, 
bacteriological, clinical and other indices in 
patients. Under today's conditions of collective 
immunity decrease of the humanity, substantial 
growth of infectious diseases rate, chronization, 
uncontrolled and irrational use of antibacterial 
drugs, the problem of immune reactivity 
modulation acquires special relevance. 
Diagnostic criteria of control over prescription 
of immunotropic drugs are implemented 
through assessment of the complex of clinical 
and laboratory indices in patients [18, 19, 20]. 
Clinical and immune criteria of effectiveness 
are determined by respective specialists with 
due account for preliminary approbation of the 
recommended actions. Immunotropic drugs, 
according to some classifications, divide into 
groups that induce various effects. These 
effects are quite numerous and are presented: 
1. Stimulation of immune cells formation 
due to the influence on the hemopoiesis system 
(colony-stimulating factors).  
2. Interaction with specific receptors of 
immunocompetent cells. 
3. Stimulation or suppression of cytokines 
release. 
4. Formation of active (vaccine) or passive 
(serum) antiinfection immunity. 
5. Normalization of microecological status 
of organism (eubiotics). 
6. Provision of energy needs and plastic 
components for immune reactions (macro-, 
microelement, vitamins, biological additives, 
antihypoxic drugs). 
7. Activation of the processes of 
detoxification of immune reaction products 
(hepatoprotectors, enteral sorbents, afferent 
methods). 
8. Elimination of antigens (adsorbents) 
from organism.  
9. Substitution therapy (thymus drugs, 
immunoglobulins, white-cell-rich suspension). 
10. Direct action on antigens (antiviral 
drugs) [21, 22]. 
Objectives: On clinical data of various 
models of pyoinflammatory diseases – deep 
pyodermia, chronic salpingooforititis, chronic 
pyelonephritis, authors found a significant 
mechanism of influence the pathogenesis on 
the manifestation of immunopathology, 
efficacy and mechanisms of pharmacological 
immunocorrection action. 
 
Materials and Methods 
In investigation was included of 300 
patients:100 patients suffered from deep 
pyodermia in the stage of exacerbation (EDP), 
100 – from chronic pyelonephritis in the stage 
of exacerbation (ECPN), 100 women – from 
chronic salpingooopharitis (ECSO) at the age 
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from 18 to 60 and 30 healthy patients -
momentary donors. The patients in each 
nosologic form were divided into two equal 
groups and were undergone a standard 
treatment and a supplementary one which 
included a modulators: galavit, roncoleukin, 
lycopide, roncoleukin with lycopide, 
superlymph, derinate, superlymph with 
derinate, polyoxidonium, thymogen, thymogen 
with polyoxidonium in reglamented doses. 
Before and after the treatment the patients 
were undergone a standard examination to 
reveal routine hematological markers of 
inflammation, common immunological factors 
(population, subpopulation of lymphocytes, 
serum immunoglobulins, cytokines, 
absorptional and metabolic ability of 
phagocytes) and also specific ones for concrete 
diseases – bacteriological and clinical 
parameters. As a result, the diagnostic material, 
taken from skin foci, urine, vaginal secrete, was 
treated by general methods and pathogenic and 
saprophyte staphylococcus, colibaccillus, 
proteus, klebsiella have been sowed and 
identified. The number of sterile tests was also 
defined. Clinical parameters included: 
intoxicational syndrome, subphebrilitis, 
lymphadenitis, renal colic, leukocyturia, 
leucorrhea discharge, hypertrophy, adnexa uteri 
disorders, etc. 
The accuracy of the results was provided 
by the rational arrangement of patients groups, 
taking into account the criteria of including and 
excluding, randomization, representation, and 
statistic processing of data with a proper 
distribution of parameters: frequency and 
resulting frequency, graphical. Ranging 
analysis, formalization of immunopathology 
and modulation mechanisms by formulas of 
immune system disorders (FDIC) and targets of 
correction (FTC) [22, 23, 23, 25, 26, 27]. 
Results and discussion  
During our study we have determined a 
universal standard reaction of routine 
hematological tests on the inflammatory 
conditions in patients with EDP, ECPN and 
ECSO: leukocytosis, neutrophilia, eosinophilia, 
monocytosis, lymphopenia, ESR acceleration. 
In the case of PID relatively to TCPN higher 
leukocytosis and the neutrophilia have been 
registrated, relatively to ESCO – a sufficiently 
less monocytosis and ESR have been observed, 
the patients with ESCO had an advantage over 
those with ECPN – according to the number of 
neutrophiles and monocytes. 
A typical character in all the cases of PID 
has been expressed in the tendency to 
disbalance or suppression of T-section 
immunity, humoral activation, suppression of 
phagocytes defense, a definite risk of the 
development of autoagressive and toxic 
conditions, an accumulation of 
proinflammatory cytokines, see fig. 1-3. 
 
А. APP
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В. ESCO 
 
Fig. 1. Differences in hematological parameters from the normal level in the acute period  
of PID of various genesis 
Note: Leuk. – leukocytes, Lymph – lymphocytes, Neut. – neutrophils, EOS – eosinophils, Mon. – 
monocytes,  ESR – exacerbation sedimentation rate, * – reliability of differences from the norm level 
at P <0.05, on the vertical axis – % of patients with 2-3 DIF / HIS 
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Fig. 2. Graphic visualization of differences in immunologic indexes from the normal level in patients 
with EDP before the treatment 
Note: Tr-T-regulators, B – B-cells, IgA, IgM, IgG – immune globulins, CIC – circulating immune 
complexes, MMM – molecules of moderate mass, LIN – leucocytes with integreen receptors, PI, PN – 
phagocyte index and number, NBTsp, NBTac – spontaneous and activated tests with nitro blue 
tetrasolium, IL-4, IL- 6, I IL- 8 – interleukins, TNFα – tumor necrosis factor, Ma – apoptosis marker, 
T – T-cells, Th – T-helpers, Tc – T-cytotoxics, Tac – T-active, NKr – natural killers regulators, NKc – 
natural killers cytotoxics, NKt – natural killers thymus dependent, * – evidence of differences from 
norm in p<0.05, punctual line – normal meaning of parameters of healthy people, broken line – 
meanings of parameters of sick people 
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Fig. 3.Graphic visualization of differences in immunologic indices from norm  
in patients with ECPN before the treatment 
 
Note: Tr-T-regulators, B – B-cells, IgA, IgM, IgG – immune globulins, CIC – circulating immune 
complexes, MMM – molecules of moderate mass, LIN – leucocytes with integreen receptors, PI, PN – 
phagocyte index and number, NBTsp, NBTac – spontaneous and activated tests with nitro blue 
tetrasolium, IL-4, IL- 6, I IL- 8 – interleukins, TNFα – tumor necrosis factor, Ma – apoptosis marker, 
T – T-cells, Th – T-helpers, Tc – T-cytotoxics, Tac – T-active, NKr – natural killers regulators, NKc – 
natural killers cytotoxics, NKt – natural killers thymus dependent, * – evidence of differences from 
norm in p<0.05, punctual line – normal meaning of parameters of healthy people, broken line – 
meanings of parameters of sick people. 
 
While assessing the dynamics of moderate 
numbers of immunological indices from normal 
significance, and the outcomes of frequency 
and resulting frequency analysis, the most 
variations have been revealed in patients with 
ECPN (50), ESCO (45), EDP-38 tests. The 
determination of the level of immunologic 
indices changes has shown its moderate 
expressiveness in IDP cases and sufficient – in 
ECPN and ESCO cases. 
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Fig. 4. Graphic visualization of differences in immunologic indices from norm in patients with ESCO 
before the treatment 
Note: Tr-T-regulators, B – B-cells, IgA, IgM, IgG – immune globulins, CIC – circulating immune 
complexes, MMM – molecules of moderate mass, LIN – leucocytes with integreen receptors, PI, PN – 
phagocyte index and number, NBTsp, NBTac – spontaneous and activated tests with nitro blue 
tetrasolium, IL-4, IL- 6, I IL- 8 – interleukins, TNFα – tumor necrosis factor, Ma – apoptosis marker, 
T – T-cells, Th – T-helpers, Tc – T-cytotoxics, Tac – T-active, NKr – natural killers regulators, NKc – 
natural killers cytotoxics, NKt – natural killers thymus dependent, * – evidence of differences from 
norm in p<0.05, punctual line – normal meaning of parameters of healthy people, broken line – 
meanings of parameters of sick people 
 
A detailed study of the immunologic 
mechanisms in concrete nosologic forms of 
pyoinflammatory diseases (PID) has revealed 
their dependence from pathogenesis. Thus 
FDIS decoding showed, that in EDP there was 
observed the accumulation of markers of the 
autoimmune processes (CIC), cytotoxic natural 
killers and anti-inflammatory cytokine (IL4). In 
ECPN – activation of humoral section of 
immunity in B-cells and MCM, the increase of 
cytotoxic lymphocytes, in TSCO – the presence 
of inflammation, disbalance of 
immunoglobulins of class G and T-cells. The 
data obtained have the evidence that despite the 
typical immunological body reaction on the 
general inflammation, there are concrete 
pathologies, dependent upon pathogenesis of 
diseases having a diagnostic significance. 
Since the assessment and direct 
comparison of action effectiveness in the 
differentiated complex immunotherapy PID of 
different genesis with galavite between various 
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nosoforms of disorders due to clear reasons was 
incorrect, the analysis was done  according to 
the correctors own effect, independent from the 
immunotropic activity of a traditional disease 
treatment. For this purpose we used a 
corresponding mathematic method. The data 
obtained are presented on figures 5-7 and in 
formulas of targets of galavite 
immunocorrection (FTI). 
 
Fig. 5. Graphic visualization of galavite‘s own effect in patients with EDP 
 
Note: Tr-T-regulators, B – B-cells, IgA, IgM, IgG – immune globulins, CIC – circulating, 
MMM – molecules of moderate mass, LIN – leucocytes with integreen receptors, PI, PN – 
phagocyte index and number, NBTsp, NBTac – spontaneous and activated tests with nitro blue 
tetrasolium, IL-4, IL- 6, IIL- 8 – interleukins, TNFα – tumor necrosis factor, Ma – apoptosis 
marker, T – T-cells, Th – T-helpers, Tc – T-cytotoxics, Tac – T-active, NKr – natural killers 
regulators, NKc – natural killers cytotoxics, NKt – natural killers thymus dependent, * – 
evidence of differences from normin, p<0.05, punctual line – normal meaning of parameters of 
healthy people, broken line – meanings of parameters of sick people. 
Circumference – normal parameters of patients after traditional treatment 
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Fig. 6. Graphic visualization of galavite‘s own effect in patients with ECPN 
 
Note: Tr-T-regulators, B – B-cells, IgA, IgM, IgG – immune globulins, CIC – circulating immune 
complexes, MMM – molecules of moderate mass, LIN – leucocytes with integreen receptors, PI, PN – 
phagocyte index and number, NBTsp, NBTac – spontaneous and activated tests with nitro blue 
tetrasolium, IL-4, IL- 6, I IL- 8 – interleukins, TNFα – tumor necrosis factor, Ma – apoptosis marker, 
T – T-cells, Th – T-helpers, Tc – T-cytotoxics, Tac – T-active, NKr – natural killers regulators, NKc – 
natural killers cytotoxics, NKt – natural killers thymus dependent, * – evidence of differences from 
norm in p<0.05, punctual line – normal meaning of parameters of healthy people, broken line – 
meanings of parameters of sick people 
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Fig. 7. Graphic visualization of galavite‘s own effect in patients with ESCO 
 
Note:  Tr-T-regulators, B – B-cells, IgA, IgM, IgG – immune globulins, CIC – circulating immune 
complexes, MMM – molecules of moderate mass, LIN – leucocytes with integreen receptors, PI, PN – 
phagocyte index and number, NBTsp, NBTac – spontaneous and activated tests with nitro blue 
tetrasolium, IL-4, IL- 6, I IL- 8 – interleukins, TNFα – tumor necrosis factor, Ma – apoptosis marker, 
T – T-cells, Th – T-helpers, Tc – T-cytotoxics, Tac – T-active, NKr – natural killers regulators, NKc – 
natural killers cytotoxics, NKt – natural killers thymus dependent, * – evidence of differences from 
norm in p<0.05, punctual line – normal meaning of parameters of healthy people, broken line – 
meanings of parameters of sick people 
 
It was found out that under the galavite 
influence the patients with EDP have undergone 
some evident changes from the initial level 5 
laboratory indices in 24 studied. The 
concentrations of IgM, phagocytes number have 
increased but NBTsp, the level of FNO and cells 
with apoptosis marker have decreased. The key 
targets of modulator in EDP were TNF
-
3Ma
-
3IgM
+
2
-
.  
In patients with ECPN the same 
preparation resulted in a significant dynamics 
from the initial level of 7 immunologic tests – a 
phagocyte index NBTac, IL-4, -6, -8 with a 
stimulating vector and NBTsp, IgG –with 
suppressing. The main points in the immune 
system of galavite modulator in ECPN were 
tests (PI
+
3NBTsp
+
3 IgG
-
3). 
In women suffering from ESCO under the 
influence of galavite modulator has been 
achieved a mathematically significant change 
of 7 indices but their spectrum turned out to be 
different. The number of Th, Tac, Tr, NKt, 
IgA, -M concentrations have increased, CIC – 
have decreased. The main effect of the 
corrector has been produced on NKt
+
3CIC
-
3IgM
-
3. 
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These results show that the key targets in 
the immune system of the galavite modulator in 
patients with IDP, ECPN, ESCO have been 
different. 
Preliminary studies have shown that the 
traditional therapy PID, in general, did not 
provide a complete correction of the changed 
clinical laboratory indices as a supplementary 
method of treatment a galavite modulator has 
been used. 
Table 1  
Rating assessment of differentiate treatment effectiveness in DIP in ranges 
 
Treatment 
Indices 
N.L. 
Summa of 
ranges 
Effectiveness 
Nosoform 
of PID 
Hem. 
М  N 
Bact. 
М  N 
Clin. 
 М  N 
Imm. 
М  N 
ТT 1  2 1  2 1  1 3  2 4 17 6  
EDP +Gal 1  1 1  2 1  1 3  1 3 14 4 
ТT 1  2 1  2 1  1 3  2 4 17 6  
ECPN +Gal 1  1 1  2 1  1 3  1 3 14 4 
ТT 2  3 3  2 1  3 3  2 3 22 5  
ESCO +Gal 1  3 2  1 1  1 3  1 3 16 2 
 
Note: ТT – traditional treatment, Gal – galavite, Hem – hematologic, Bact – bacteriologic, Clin -
clinical, Imm  – Immunologic indices, МN – mobile and normalizing effects, N.L. – number of strong 
correlation links, 1 2 – maximal and moderate ranges of effectiveness. 
 
Due to the table data, a supplementary role 
of galavite at the background of the traditional 
treatment of all the PID nosoforms according to 
the outcome rating has provided an evident 
increase of its effectiveness in hematological, 
bacteriological, immunological and clinical 
indices. Besides, the preparation activity was 
higher in ESCO patients. 
While analyzing the obtained data, we 
have documented the phenomena of typical 
variations formation of hemato-immunological 
inflammation markers, independent from PID 
pathogenesis. They were in the form of 
leukocytes masses, granulocytes, monocytes, 
accelerated ESR, disbalance or suppression of 
some immunity sections and the induction of 
the diagnostically significant laboratory 
changes on the subpopulation, interleukin, 
immunoglobulin levels, given in the formulary 
forms. 
We have also determined qualitatively and 
quantatively differentiated clinic laboratory 
effects of combinations of traditional treatment 
with galavite, dependant from the pathogenesis 
of disorders and analyzed parameters. 
It was also found that the traditional 
uncorrected treatment of different nosoforms of 
DGT as a whole proved to be insufficiently 
effective, and in particular – differentiated 
according to the effect on the grouped and 
individual indicators of patients. At the same 
time, normalization of clinical, bacteriological, 
and less often hematological and 
immunological parameters was observed, 
which puts additional immunotherapy of 
patients on the agenda. As its variants, 
modulators of various origins were chosen; 
stimulants of local and systemic immunity; its 
various links [28]. 
As a result of the application of formalized 
analytical approaches, the clinical and 
laboratory effectiveness of complex treatment 
of patients was shown to increase and the 
declining overall rating of its variants was 
determined. With UCP: 1 – roncoleukin with 
lycopide, 2 – lycopide, 3 – galavite, 
roncoleukin; with ECPN: 1 – superlymph with 
derinatom, 2 – galavite, 3 – derinate, 4 – 
superlimph; with ESCO: 1 – polyoxidonium, 2 
– thymogen with polyoxidonium or galavite, 3 
– thymogen. The effectiveness of one 
 Zemskova V.A., Zoloedov V.I., Popova O.A. Optimization immunepharmacotherapy of 
pyoinflammatory diseases. Research results in Pharmacology. 2017;3(4):160-176. 
172 
 
December. 2017. 3(4). Research Results in Pharmacology rrpharmacology.ru 
traditional treatment in all cases was less 
pronounced. 
Phenomena for achieving a new quality 
with a combination of modulators of different 
origin and mechanism of action relative to 
monoactivity have been established, as well as 
increasing the formation of standard formulas 
of immune system disorders of strong 
correlation links in the process of complex 
treatment of patients, tabl. 2, 3. 
 
Table 2  
Signal targets in the lymphoid system of differentiated immunotherapy of PID of various genesis 
 
Treatment   FIT FISD 
EXTENSION OF DEEP PYODERMIA 
Тraditional treatment В+3Тс
+
3NBTsp
+
3 IL8
+
3NKc
+
3Ма
+
3 
+roncoleukin Таc+3IgG
¯
3Т
+
3 IgM
+
3 CIC
+
2Таc
+
2 
+lycopide FI
+
3NBTac
+
3IL6
-
3 Тr
+
3IgA
+
3Тc
-
2 
+galavit IL4
+
3TNF
¯
3Ма
+
3 IL6
+
3NBTsp
+
3IL4
+
3 
+roncoleukin +lycopide NBTsp
+
3Тc
+
3Тh
+
3 NKc
+
3IgG
+
3IL4
+
3 
EXTENSION OF CHRONIC PYELONEPHRITIS 
Тraditional treatment Т+3IgA
+
3 CIC
 ¯
2 NKc
+
3IgM
+
3TNF
+
2 
+superlimph Тr+3В
+
3Тc
+
3 Тr
+
3IgM
+
3NKt
+
3 
+derinate NBTsp
+
3FN
+
3NKr
+
3 Т
¯
2FI
+
3IgG
+
3 
+galavit FI
+
3IL4
+
3Тr
¯
2 FI
+
3IL4
+
3Тr
+
3 
+superlimph +derinate Тh+3Тr
+
3 CIC
¯
3 В
+
3FI
+
3Тc
+
3 
EXTENSION OF CHRONIC SALPINGFOORITIS 
Тraditional treatment Таc¯2IgM
+
2Тh
¯
2 IL8
+
3NKc
+
3Ма
+
3 
+thymogen Тh+3Тc
+
3 NKr
+
3 IgM
+
3 CIC
+
2Таc
+
2 
+polyoxidonium Тr+3NBTsp
+
3FN
+
3 Тr
+
3IgA
+
3Тc
-
2 
+galavit FN
+
3IL4
+
3NKt
+
3 TNF
+
3В
+
3FI
+
3 
+thymogen +polyoxidonium Тh+3NBTac
+
3МSМ
-
3 NKc
+
3IgG
+
3IL4
+
3 
Note: ТT – traditional treatment, Gal – galavite, Hem – hematologic, Bact – bacteriologic, Clin -
clinical, Imm  – Immunologic indices, МN – mobile and normalizing effects, N.L. – number of strong 
correlation links, 1 2 – maximal and moderate ranges of effectiveness. 
 
 
Detailing the targets of correctors and 
creating programs for computers has allowed to 
formulate a simplified method of selecting 
active drugs for individual nosoforms for key 
laboratory markers. A six-level algorithm for 
the detection and treatment of 
immunocompromised contingents has been 
singled out and protected. 
The first, prelaboratory, preliminary, on 
the basis of the questionnaire, the certificate for 
the computer program No. 2014519643. 
The second, auxiliary on the basis of 
immunotropic treatment, the certificate for the 
computer program № 2015612811. 
The third, unified on the basis of the 
formulas of the immune system disorders, the 
certificate for the computer program 
№2015614977. 
The fourth, summarized on the basis of 
grouped indicators, certificate for the computer 
program No. 2015612811. 
The fifth, detailed, based on a complete 
analysis of the immune status,  certificate for 
the computer program No. 2014619846. 
The sixth, personalized, based on the 
formulas of immunocorrection targets, the 
certificate for the computer program No. 
201466056 and 2016619036. 
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Table 3  
Additional laboratory indications for the selection of differentiated immunotherapy PID 
 
Nosoform 
Recommended 
treatment 
Critical values of benchmarks 
APP Тraditional 
treatment 
В<0,2*109l,Тc<0,14*109l, NBTsp<2,9 CU 
+roncoleukin Таc<0,04*109l, Т<0,5*109, IgG>18,0 g/l 
+lycopide FI<24,3%, NBTac<7,5%,IL6<пкг/ml 
+galavit IL-4<5,5pkg/ml, TNF>0,32 pkg/ml, Ма>0,14*109л 
+roncoleukin+ 
lycopide 
В<0,2*109l,Тc<0,14*109l, NBTsp<2,9% 
ECPN Тtraditional 
treatment 
Т<0,5*109l, IgА<0,5g/k, CIC>45,9 CU 
+superlimph NKr<0,11*10
9
l, NKt<0,18*10
9
l, IL4<6,6 pkg/ml 
+derinate Т<0,03*109l, Тc<0,14*109l, В>0,6*109l 
+galavit FI<24,3%, IL4<6,6 pkg/ml Тr<0,19*109l 
+superlimph+derean
t 
Тh<0,38*109l, Тr<0,03*109l, CIC< 45,9 CU 
ESCO Тtraditional 
treatment 
Таc>0,2*109l, Тh>1,82*109l, IgМ<0,6 g/l 
+thymogen Тh<0,38*109l, Тc<0,14*109l, NKr<0,11*109l 
+polyoxidonium Тr<0,03*109l, NBTsp<2,9%, FN<2,4 mt 
+galavit FN<2,4 mt, IL4<6,6 pkg/ml, NKt<0,18*10
9
l 
+thymogen+ 
polyoxidonium 
Тh<0,38*109l, NBTsp<2,9%, МSМ>9,1 CU 
 
 
Conclusion 
1. Patients with exacerbation of deep 
pyoderma, chronic pyelonephritis, and 
salpingooophoritis were found to have standard 
hematological changes (leukocytosis, 
neutrophilia, eosinophyllosis, monocytosis, 
lymphopenia, accelerated ESR), immunological 
(imbalance of cell, humoral, phagocytic 
defense, accumulation of CIC, MSM, pro-
inflammatory cytokines), metabolic 
(suppression of antioxidant system factors, 
stimulation – free radical oxidation of lipids 
and proteins). Key formulas of laboratory 
disorders in patients have been determined, 
with the help of the diagnostic value 
coefficient. 
2. Three clinical models with PID have 
shown a qualitative typical character of the 
immunopathology – a tendency to disbalance 
and suppression of T-section immunity, the 
activation of humoral, the suppression of 
phagocyte, the increased risk of autoaggressive 
and toxic conditions development, the 
accumulation of the proinflammatory 
cytokines. 
3. It has been revealed a diagnostically 
significant influence of pathogenesis of each 
disorder on the concrete character and 
expressiveness of the immunopathology which 
was shown in individual FDIS patients: in EDP 
–CIC+3NKc
+
3Il6
+
3; in ECPN – 
B
+
3MMM
+
2Tc
+
3; in ESCO – TNF
+
3IgG
+
3T
-
2. 
4. Traditional nonimmunotropic treatment 
of PID causes uneven normalization of clinical 
and laboratory status: with APP (acute purulent 
pyelonephritis) – significant (> 66%) 
elimination of changes in bacteriological, 
clinical and secondary (33-66%) – hemato-
immunological indicators; with ECPN – 
significant – bacteriological, secondary – 
immunological, insignificant (<33%) – 
hematological, biochemical, clinical tests; at 
ECSO – average – bacteriological, 
immunological and insignificant – 
hematological and clinical parameters of 
patients. 
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5. A differentiated distribution of galavite 
action was established for laboratory 
parameters of patients with different PID: 
hematologic – significant for all nosoforms; on 
immunological – the average for ECPN, 
inessential – with APP and ECSO. The key 
effect of the modulator in the immune system 
with APP appeared to be oriented toward pro- 
and anti-inflammatory cytokines, CD95 + 
lymphocytes; with ECSO – in PI, IL4, Tr; at 
ECSO – on PN, IL4, NKt. 
6. Additional application of differentiated 
immunocorrection in complex treatment of 
APP increases its final clinical and laboratory 
significance with the following decreasing 
rating of individual drugs: 1-roncoleukin + 
lycopide, 2-lycopide, 3-roncoleukin, 4-galavit, 
5-traditional therapy. 
7. Additional appointment of patients with 
ECPN immunocorrectors causes stimulation of 
the overall activity of complex treatment with 
the following rating of individual effects:  
1-derinate + superlimph, 2-galavite, 3-derinate, 
4-superlimph, 5-traditional therapy. 
8. Additional inclusion in the conventional 
treatment of ECSO immunotropes potentiates 
its resulting efficacy with the following rating 
of the declining efficacy of specific drugs:  
1-polyoxidonium, 2-thymogen + 
polyoxidonium or galavite, 3-thymogen,  
4-traditional therapy. 
9. With the combination of modulators in 
patients with PID, it is not mechanical 
summation of the properties of individual drugs 
that is realized, but an increase in the overall 
efficiency and transformation of the reference 
targets of the complex with respect to mono-
actions. Thus, in case of APP, roncoleukin + 
lycopid causes activation of neutrophil 
metabolism, accumulation of regulatory 
subpopulations of T cells; with ECPN, 
superlymph + derinate – increase in the level of 
Th, NBTac and decrease in MSM; at ECSO 
timogen + polyoxidonium – stimulation of 
NBTsp, the number of Tc and Th. 
10. As an auxiliary method of selecting the 
optimal variants of immunotherapy for 
purulent-inflammatory diseases, it is proposed 
to detail, with the help of the diagnostic value 
coefficient, formalized targets of action (FIT) 
of individual correctors and their combinations 
for determining signal laboratory markers. 
11. A six-stage method for identifying 
immunocompromised individuals and choosing 
the optimal differential therapy for purulent-
inflammatory diseases (an electronic assistant 
to a doctor) was developed based on the 
introduction of digital results of a laboratory 
examination of patients in a computer. 
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